Palisade Bio has initiated the multiple ascending dose (MAD) cohorts of its Phase Ia/b trial for PALI-2108 in ulcerative colitis after completing single ascending dose (SAD) cohorts.
Palisade Bio is set to initiate a Phase 1 clinical trial for PALI-2108, a PDE4 inhibitor prodrug, targeting moderate to severely active ulcerative colitis (UC).
Palisade Bio identifies PDE4B expression as a potential biomarker for patient stratification in ulcerative colitis (UC), with higher expression in colitis patients.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.